The ETB is composed of three drug discovery teams, each with dedicated biologists, chemists and informatics scientists. These teams are uniquely designed to handle small molecule discovery efforts, including early assay optimization, state-of-the-art high-throughput screening, early hit selection, advanced medicinal chemistry driven by structure-activity relationships, virtual screening, and molecular modeling and docking.
Each team showcases specialized areas of expertise covering a wide spectrum of biological targets and human pathologies, including:
- 3-D cell culture and tissue/organoid models
- Advanced cell-based models of disease
- Autophagy
- Cancer
- Cellular thermal shift assays
- Deubiquitinating enzymes
- DNA damage and replication
- Epigenetics
- Enzymatic assays
- High-throughput cell-based models and high-content screening
- Immunological and differentiation assays
- Induced pluripotent stem cell–based assays (retinal pigment epithelium, neurological disorders)
- Infectious diseases
- Kinases
- Metabolic targets (cancer and inborn errors of metabolism)
- Yeast/bacterial assays